Production (Stage)
GenSight Biologics S.A.
GSGTF
$0.24
-$0.08-25.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 43.38% | 42.24% | 51.66% | 50.51% | 11.16% |
| Total Depreciation and Amortization | -68.36% | -67.73% | -13.88% | -11.85% | 211.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.42% | -81.05% | 76.07% | 75.50% | 478.60% |
| Change in Net Operating Assets | -18.81% | -17.18% | -273.21% | -277.35% | 5,679.90% |
| Cash from Operations | 34.51% | 33.19% | 55.19% | 54.13% | 47.80% |
| Capital Expenditure | 100.00% | 100.00% | -- | -- | 89.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.39% | -92.48% | -91.60% | -91.34% | -61.83% |
| Cash from Investing | -91.03% | -91.15% | -92.20% | -92.07% | -25.50% |
| Total Debt Issued | -- | -- | -- | -- | -42.76% |
| Total Debt Repaid | -754.98% | -754.98% | 74.27% | 74.27% | 95.15% |
| Issuance of Common Stock | -14.52% | -14.52% | 5,040.00% | 5,040.00% | 7,394.00% |
| Repurchase of Common Stock | 94.95% | 94.95% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 892.05% | 892.05% | 904.55% | 904.55% | 94.13% |
| Cash from Financing | -85.26% | -84.96% | 87.26% | 91.70% | 196.64% |
| Foreign Exchange rate Adjustments | -573.95% | -584.57% | -92.90% | -92.81% | -29.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -498.30% | -506.31% | 149.56% | 150.74% | 108.66% |